Evolus (EOLS) Scheduled to Post Earnings on Wednesday

Evolus (NASDAQ:EOLS) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Evolus Price Performance

EOLS stock opened at $16.42 on Tuesday. Evolus has a 52-week low of $7.74 and a 52-week high of $17.82. The business has a fifty day moving average of $16.26 and a two-hundred day moving average of $13.77. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -18.04 and a beta of 1.31. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26.

Insider Buying and Selling at Evolus

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the sale, the chief marketing officer now directly owns 82,375 shares in the company, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the transaction, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Barclays boosted their price target on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Friday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Friday, September 13th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.